ライフサイエンスコーパス: bedaquiline

1 would likely result in greater resistance to bedaquiline.

2 assuming only patients with XDR TB received bedaquiline.

3 cal efficacy and the tolerability profile of bedaquiline.

4 a mean of 71 days (26-116); 5 after starting bedaquiline.

5 agents moxifloxacin, PA-824, linezolid, and bedaquiline.

6 ude approval of two new drugs, delamanid and bedaquiline.

7 All infants were exposed to bedaquiline.

8 -TB, and mutations linked to third-line drug bedaquiline.

9 ine; and two injections with 4 weeks of oral bedaquiline.

10 ns as they power living cells and respond to bedaquiline.

11 -876 and M3 was investigated and compared to bedaquiline.

12 variants) were phenotypically susceptible to bedaquiline.

13 ean of 71 days (26-116); 6/14 after starting bedaquiline.

14 ecause of interactions between efavirenz and bedaquiline.

15 lture reversion was lower in those receiving bedaquiline (1 patient; 0.8%) than in controls (12 patie

16 All CSF measurements of bedaquiline (12), clofazimine (24), and delamanid (19) w

17 ine (5), clofazimine (5), delamanid (4), and bedaquiline (2).

18 mg three times per week (B(load)PaZ) or oral bedaquiline 200 mg daily (B(200)PaZ).

19 ) assuming all patients with MDR TB received bedaquiline, 35.1 y (34.4, 35.8) assuming patients with

20 er among patients receiving delamanid versus bedaquiline (36% vs 10%, respectively; P < .01).

21 er among patients receiving delamanid versus bedaquiline (36% vs. 10%, p <0.01).

22 n effective drugs received among patients on bedaquiline (4, IQR 4-4) and delamanid (4, IQR 3.5-5) ba

23 namide (oral 1500 mg daily) with either oral bedaquiline 400 mg daily on days 1-14 then 200 mg three

24 eference MIC quality control (QC) ranges for bedaquiline, a diarylquinoline antimycobacterial, used i

25 Bedaquiline, a potent new therapy for drug-resistant tub

26 d, our results provide support for expanding bedaquiline access to all patients with MDR TB.

27 Bedaquiline accumulated primarily in host cell lipid dro

28 Bedaquiline AD MIC quality control (QC) range for the H3

29 Bedaquiline AD MIC quality control (QC) range for the H3

30 ncluded one or two injections of long-acting bedaquiline (alone or with oral bedaquiline with or with

31 Bedaquiline, an antitubercular drug that targets ATP-syn

32 Bedaquiline, an ATP synthase inhibitor, is the spearhead

33 f activity after an injection of long-acting bedaquiline and 2) evaluate the activity of regimens com

34 Patients with low adherence (<85%) to both bedaquiline and ART were identified as high-risk for poo

35 Separate EDM devices measured adherence for bedaquiline and ART.

36 alyses, the lowest P values for clearance of bedaquiline and clofazimine were with RFX4 rs76345012 (P

37 oduction of MmpL5 confers resistance towards bedaquiline and clofazimine, key drugs to combat multidr

38 luate the efficacy and safety of concomitant bedaquiline and delamanid administration.

39 Bedaquiline and delamanid are newly available drugs for

40 Bedaquiline and delamanid are newly available drugs for

41 ort show that regimens including concomitant bedaquiline and delamanid for longer than 24 weeks are e

42 inistration of the PRS regimen V antibiotics bedaquiline and delamanid on top of the oral regimen wou

43 he emergence of resistance to new therapies, bedaquiline and delamanid.

44 e common than those frequently attributed to bedaquiline and delamanid.

45 activity: one injection with 2 weeks of oral bedaquiline and high-dose rifapentine; and two injection

46 In multivariate analyses, bedaquiline and levofloxacin, drugs often used in combin

47 Coresistance to bedaquiline and linezolid and clofazimine and linezolid

48 of Mtb by BPaL, a combination of pretomanid, bedaquiline and linezolid that is used to treat highly d

49 rug-resistant tuberculosis regimen including bedaquiline and linezolid.

50 We observed cell wall damage induced by bedaquiline and moxifloxacin through secondary effects d

51 Moreover, verapamil reduced tolerance to bedaquiline and moxifloxacin.

52 s of bedaquiline treatment-naive patients to bedaquiline and other antituberculosis drugs by the 7H9

53 Finally, because resistance to bedaquiline and other antituberculosis drugs is caused b

54 tment, for preventing acquired resistance to bedaquiline and other MmpS5L5 substrates, while also pro

55 uaramides have a different binding site than bedaquiline and possess the potential to inhibit bedaqui

56 ed mice were treated for up to 13 weeks with bedaquiline and pretomanid combined with moxifloxacin an

57 ses of peripheral neuropathy when given with bedaquiline and pretomanid.

58 istant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, di

59 nce assays could facilitate effective use of bedaquiline and surveillance of drug resistance emergenc

60 Bedaquiline and the M2 metabolite plasma concentrations

61 resistant TB or MDR-TB who were treated with bedaquiline and/or delamanid underscores the need for ur

62 tant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatmen

63 fety of longer MDR/RR-TB regimens containing bedaquiline and/or delamanid.

64 who received MDR/RR-TB treatment containing bedaquiline and/or delamanid.

65 MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequa

66 Administration of bedaquiline and/or linezolid improved treatment outcomes

67 stant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine,

68 ations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine)

69 extensively drug-resistant (XDR) TB received bedaquiline, and 34.9 y (34.6, 35.2) assuming only patie

70 Fifty-eight (54%) women received bedaquiline, and 49 (45%) babies were exposed to bedaqui

71 Both pharmacologic treatment, with bedaquiline, and a genetic mutant lacking uvrA modified

72 with sequential monotherapy: clarithromycin, bedaquiline, and clofazimine, with only one drug adminis

73 0% were likely to be sensitive to linezolid, bedaquiline, and delamanid.

74 all-oral regimen that included levofloxacin, bedaquiline, and linezolid, or the standard-of-care (SOC

75 regimens, an all-oral 6-month levofloxacin, bedaquiline, and linezolid-containing MDR/RR-TB regimen

76 Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquire

77 Delamanid, bedaquiline, and pretomanid have been recently added in

78 ity rates of patients with XDR not receiving bedaquiline, and promising cohort study results, suggest

79 Bedaquiline, another antibiotic commonly used in combine

80 mpS5L5 efflux pump reduces susceptibility to bedaquiline as well as its new, more potent derivative T

81 d Main Results: One injection of long-acting bedaquiline at 160 mg/kg exerted antituberculosis activi

82 rt study, children aged 6-17 years receiving bedaquiline at recommended doses as part of MDR/RR-TB tr

83 The explored strategies included making bedaquiline available to all patients with MDR TB, restr

84 linical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an ex

85 Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), wit

86 t strategies for introducing the new TB drug bedaquiline based on patients' resistance patterns.

87 f effective drugs received among patients on bedaquiline-based (4; interquartile range [IQR], 4-4) an

88 B, 100 were enrolled and 95 were receiving a bedaquiline-based (n = 64) or delamanid-based (n = 31) r

89 Bedaquiline-based oral short-course regimens (SCR) for r

90 5 to -0.13) log(10) eCFU/ml for the all-oral bedaquiline-based regimen (P = 0.054), and -0.29 (95% CI

91 Among patients with MDR-TB, bedaquiline-based regimens were associated with higher r

92 Among patients with MDR TB, bedaquiline-based regimens were associated with higher r

93 nization recommended a switch to an all oral bedaquiline-based second-line regimen for treatment of d

94 t, subjects with DR-TB receiving an all oral bedaquiline-based second-line treatment regimen displaye

95 njectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.

96 IV (28 women, 27 men) who were receiving new bedaquiline-based treatment for DRTB, concurrent with an

97 he PRAXIS study within 2 weeks of initiating bedaquiline-based treatment for DRTB.

98 ica updated its all-oral regimen, to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for al

99 Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rif

100 nes associated with phenotypic resistance to bedaquiline (BDQ) and delamanid (DLM) in Mycobacterium t

101 Mumbai, India has been providing concomitant Bedaquiline (BDQ) and Delamanid (DLM) in treatment regim

102 ica updated its all-oral regimen, to include bedaquiline (BDQ) and two months of linezolid (LZD) for

103 The approval of bedaquiline (BDQ) for the treatment of tuberculosis has

104 e found that the anti-tuberculosis (TB) drug bedaquiline (BDQ) is localised not only in foamy macroph

105 Bedaquiline (BDQ) is the first new drug for tuberculosis

106 Bedaquiline (BDQ) resistance presents a critical challen

107 Emerging resistance to bedaquiline (BDQ) threatens to undermine advances in the

108 Bedaquiline (BDQ), a diarylquinoline antibiotic that tar

109 New anti-TB drugs bedaquiline (BDQ), delamanid (DLM) and pretomanid (PTM)

110 Bedaquiline bioavailability was 57% of that in adults.

111 Binary phenotyping based on the bedaquiline breakpoint might be inappropriate to monitor

112 5 mug/ml by AD were consistent with previous bedaquiline breakpoints.

113 25 ug/ml by AD were consistent with previous bedaquiline breakpoints.

114 populations may help explain the more rapid bedaquiline clearance reported in Africans.

115 sity were associated with 15% and 30% slower bedaquiline clearance, respectively.

116 culosis, CYP3A5*3 was associated with slower bedaquiline clearance.

117 ge time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and

118 The use of bedaquiline combined with other active drugs has the pot

119 eight was reported in more babies exposed to bedaquiline compared to babies not exposed (45% vs 26%;

120 clear genotypic-phenotypic associations for bedaquiline complicates the development of molecular dru

121 were highest at the 0.25, 0.12, and 1 mug/ml bedaquiline concentrations for the AP method, BMD (froze

122 parameter sets, for parameter sets in which bedaquiline conferred high risks of added mortality and

123 to -0.20) log(10) eCFU/ml for the injectable bedaquiline-containing regimen (P = 0.019), -0.35 (95% C

124 At current costs, the oral bedaquiline-containing regimen for rifampicin-resistant

125 V on antiretroviral therapy (ART) initiating bedaquiline-containing regimens in KwaZulu-Natal, South

126 s on antiretroviral therapy (ART) initiating bedaquiline-containing regimens in KwaZulu-Natal, South

127 In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM

128 Both bedaquiline-containing regimens, a 9-month oral regimen

129 Bedaquiline-containing regimens, now the first-line ther

130 y in patients who have received unsuccessful bedaquiline-containing regimens.

131 and December 2015: ceftaroline, fidaxomicin, bedaquiline, dalbavancin, tedizolid, oritavancin, ceftol

132 in the four genes of interest and phenotypic bedaquiline data in both clinical and non-clinical sampl

133 gs for TBM treatment, whereas the utility of bedaquiline, delamanid, and clofazimine is uncertain giv

134 ole of newer and repurposed drugs (including bedaquiline, delamanid, and linezolid), pharmacokinetic

135 two resistance mutations were classified for bedaquiline, delamanid, clofazimine, and linezolid as pr

136 >/=60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases.

137 s, 1 (7%) had an adverse event necessitating bedaquiline discontinuation.

138 ents, one had an adverse event necessitating bedaquiline discontinuation.

139 tiation with fixed-dose combinations without bedaquiline drug interactions should be strongly conside

140 Bedaquiline Drug Resistance Emergence Assessment in Mult

141 ve criteria to facilitate routine phenotypic bedaquiline DST and to monitor the emergence of bedaquil

142 ch and provide guidance for routine clinical bedaquiline DST in laboratories worldwide.

143 Bedaquiline DST methodologies and MIC QC ranges against

144 The most highly reproducible bedaquiline DST methods were MGIT960 and BMD using dry p

145 Two tier-2 QC reproducibility studies of bedaquiline DST were conducted in eight laboratories usi

146 he periplasm is essential for mycobactin and bedaquiline efflux by MmpL4 and MmpL5.

147 sible from the cytosol and also required for bedaquiline efflux.

148 ong patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 a

149 Data on patients started on bedaquiline for MDR TB between September 2012 and August

150 Data on patients started on bedaquiline for MDR TB between September 2012 and August

151 continued taking SLIs, supporting the use of bedaquiline for MDR tuberculosis treatment in programmat

152 Substituting bedaquiline for SLIs in MDR tuberculosis treatment resul

153 ompletion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.

154 ent completion in this series support use of bedaquiline for the treatment of MDR/XDR TB.

155 ur position in favour of increased access to bedaquiline for these patients is based on three argumen

156 rval [CI] -0.23 to -0.12) for the injectable bedaquiline-free reference regimen, the killing rates we

157 Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for

158 and Drug Administration approved the use of bedaquiline fumarate as part of combination therapy for

159 There were 10 deaths in the bedaquiline group and 2 in the placebo group, with no ca

160 sis, cure rates at 120 weeks were 58% in the bedaquiline group and 32% in the placebo group (P=0.003)

161 There were more deaths in the bedaquiline group than in the placebo group.

162 ccurred in 35 of 146 (23.9%) patients in the bedaquiline group versus 51 of 141 (36.2%) in the contro

163 rom 125 days to 83 days (hazard ratio in the bedaquiline group, 2.44; 95% confidence interval, 1.57 t

164 Bedaquiline has been a wonder drug in the treatment of m

165 bal rollout of the new antituberculosis drug bedaquiline has been slow, in part reflecting concerns a

166 Conclusions: Long-acting injectable bedaquiline has significant potential for shortening tub

167 Two new drugs, delamanid and bedaquiline, have recently been approved for treatment o

168 Here we investigate bedaquiline hyper-susceptibility in drug-resistant Mycob

169 Bedaquiline improves treatment outcomes in patients with

170 ion microscopy to image the distribution of bedaquiline in infected human macrophages at submicromet

171 atment outcomes, safety, and tolerability of bedaquiline in our case series.

172 atment outcomes, safety, and tolerability of bedaquiline in our case series.

173 within a single bacterial chromosome, use of bedaquiline in patients with XDR tuberculosis will not s

174 istance concerns should not forestall use of bedaquiline in patients with XDR tuberculosis.

175 quiline, and 49 (45%) babies were exposed to bedaquiline in utero.

176 flux redirection explains the idiosyncratic bedaquiline-induced increase in O(2) consumption rates p

177 same approach to human cells did not detect bedaquiline-induced inhibition of mitochondrial function

178 P synthase nor inhibition of ATP synthase by bedaquiline inhibited the dibucaine-induced de-partition

179 h culture-positive pulmonary tuberculosis at bedaquiline initiation.

180 R plus additional resistance and withholding bedaquiline introduction completely.

181 Bedaquiline is a core drug for the treatment of multidru

182 Bedaquiline is a critical component of new drug-resistan

183 Bedaquiline is a crucial drug for control of rifampicin-

184 Bedaquiline is a life-saving tuberculosis drug undergoin

185 Bedaquiline is a new antibiotic that was approved for th

186 ed contacts will face equivalent outcomes if bedaquiline is either not provided because of policy, or

187 Acquired resistance to bedaquiline is especially likely in patients with extens

188 Bedaquiline is the cornerstone of a new regimen for the

189 Bedaquiline is used as a substitute for second-line inje

190 Access to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate,

191 (5.8%) in the strategy group with an initial bedaquiline-linezolid regimen (adjusted difference, 0.8

192 y involving initial treatment with an 8-week bedaquiline-linezolid regimen was noninferior to standar

193 cificity, and reproducibility of provisional bedaquiline MIC breakpoints and World Health Organizatio

194 Bedaquiline MIC frequency, mode, and geometric mean were

195 lidated the sensitivity and specificity of a bedaquiline MIC susceptibility breakpoint of 0.12 mug/ml

196 obiological equivalence was demonstrated for bedaquiline MICs determined using 7H10 agar and 7H11 aga

197 ed using 7H10 agar and 7H11 agar but not for bedaquiline MICs determined using 7H9 broth and 7H10 aga

198 .1% (207/211, with one data set excluded) of bedaquiline MICs.

199 d) or 95.9% (7H11 agar dilution; 232/242) of bedaquiline MICs.

200 t, the use of drug combinations that include bedaquiline might prevent spread of XDR disease to other

201 sourced M tuberculosis isolates and measured bedaquiline minimum inhibitory concentrations (MICs).

202 In patients with multibacillary leprosy, bedaquiline monotherapy cleared M. leprae by 4 weeks of

203 untreated multibacillary leprosy to receive bedaquiline monotherapy for 8 weeks.

204 In addition, LRM-DST results for bedaquiline, moxifloxacin, imipenem, linezolid, and cefo

205 B, 100 were enrolled and 95 were receiving a bedaquiline (n=64) or delamanid (n=31) based regimen.

206 conds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug.

207 ant tuberculosis to receive either 400 mg of bedaquiline once daily for 2 weeks, followed by 200 mg t

208 inezolid only, 0.40 (95% CI, 0.21-0.77) with bedaquiline only, and 0.21 (95% CI, 0.12-0.38) with both

209 patients with MDR TB in Georgia receiving a bedaquiline or delamanid-based treatment regimen.

210 Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed po

211 ase in MICs was observed for clarithromycin, bedaquiline, or clofazimine across treatment phases, ind

212 specific use of moxifloxacin, levofloxacin, bedaquiline, or linezolid were associated with significa

213 with MDR-TB in Georgia who were receiving a bedaquiline- or delamanid-based treatment regimen.

214 5*3) was associated with slower clearance of bedaquiline (P = .0017) but not M2 (P = .25).

215 A bedaquiline pharmacokinetic model was adapted to be allo

216 ctivity of regimens comprised of long-acting bedaquiline plus short (2-4 wk) oral companion courses o

217 t tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or wi

218 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regi

219 vestigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bacte

220 n lower efficacy than what was observed when bedaquiline, pretomanid, and linezolid are coadministere

221 sociated with at least a 2-fold reduction in bedaquiline, pretomanid, and linezolid exposures in mice

222 teractions, coadministration of BTZ-043 with bedaquiline, pretomanid, and linezolid in combotherapy i

223 The combination of bedaquiline, pretomanid, and linezolid led to a favorabl

224 include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without m

225 m results of a novel 6 month 3-drug regimen (bedaquiline, pretomanid, and linezolid).

226 Bedaquiline, pretomanid, and linezolid, with or without

227 n stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BP

228 h regimen containing a potent combination of bedaquiline, pretomanid, linezolid, and moxifloxacin is

229 tivity and safety profile of combinations of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide

230 4 to 93% of the participants across all four bedaquiline-pretomanid-linezolid treatment groups had a

231 Among participants who received bedaquiline-pretomanid-linezolid with linezolid at a dos

232 cidification, and the ATP synthase inhibitor bedaquiline prevents ATP-driven acidification but not su

233 d, ethambutol, pyrazinamide) or second-line (bedaquiline, pyrazinamide, levofloxacin, linezolid, clof

234 e determine the effect of the ETC inhibitors bedaquiline, Q203 and clofazimine on the Mtb ETC, and th

235 Bedaquiline reduced the median time to culture conversio

236 -4.9]; P = 0.003) after censoring those with bedaquiline replacement in the SOC arm (and this pattern

237 trategies consistently increased the risk of bedaquiline resistance but decreased the risk of resista

238 2020, that assessed genotypic and phenotypic bedaquiline resistance in clinical or non-clinical Mycob

239 Clinical bedaquiline resistance in Mycobacterium tuberculosis has

240 will not substantially increase the risk of bedaquiline resistance in patients with drug-susceptible

241 nthase but the predominant route to clinical bedaquiline resistance is via upregulation of the MmpS5L

242 Clinical bedaquiline resistance predominantly involves mutations

243 Bedaquiline resistance was common in this cohort of indi

244 r pepQ), with 201 (20.6%) showing phenotypic bedaquiline resistance.

245 and repeat susceptibility test had acquired bedaquiline resistance.

246 aquiline DST and to monitor the emergence of bedaquiline resistance.

247 in part reflecting concerns about spread of bedaquiline resistance.

248 Bedaquiline-resistance gain, for which we identified ris

249 Absence of cross resistance against bedaquiline resistant mutants suggested a different bind

250 subinhibitory drug concentrations to select bedaquiline-resistant and clofazimine-resistant mutants.

251 Most bedaquiline-resistant infections were attributable to re

252 particular enrichment of truncated MmpR5 in bedaquiline-resistant isolates resulting from either fra

253 o 15 (7%) of 208 mutations found in clinical bedaquiline-resistant isolates.

254 Emergence of bedaquiline-resistant Mycobacterium tuberculosis (Mtb) t

255 inical use is threatened by the emergence of bedaquiline-resistant strains of Mycobacterium tuberculo

256 and is active against multidrug- as well as bedaquiline-resistant strains.

257 quiline and possess the potential to inhibit bedaquiline-resistant strains.

258 nced isolates, 14% (n=89) were genotypically bedaquiline-resistant, 67% (n=60) of which were in clust

259 However, the mechanisms underlying bedaquiline's efficacy against MDR-TB remain unknown.

260 Bedaquiline shows potential for the treatment of M. intr

261 Of particular importance is bedaquiline (Sirturo), which kills mycobacteria by inhib

262 Bedaquiline (Sirturo, TMC207), a diarylquinoline that in

263 Data from 162 patients who received bedaquiline substitution and 168 controls were analyzed;

264 retrospective cohort study adults receiving bedaquiline substitution for MDR tuberculosis therapy, p

265 atients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regim

266 Bedaquiline targets mycobacterial ATP synthase but the p

267 ighlight verapamil's potential for enhancing bedaquiline TB treatment, for preventing acquired resist

268 ition of the safety and mortality benefit of bedaquiline, the finding that the 9-11 month injectable-

269 After completing the 8-week course of bedaquiline, the patients started standard multidrug the

270 -line antitubercular agents (moxifloxacin or bedaquiline), these HDTs significantly reduce bacterial

271 Like the approved drug bedaquiline, these compounds achieve efficacy by inhibit

272 With a particular focus on bedaquiline (TMC207), the first anti-TB drug of a novel

273 mycin, amikacin, cefoxitin, tigecycline, and bedaquiline (TMC207).

274 The addition of bedaquiline to a preferred background regimen for 24 wee

275 Although providing bedaquiline to all MDR patients resulted in the highest

276 The approval of bedaquiline to treat tuberculosis has validated adenosin

277 er tuberculosis-specific benefits noted with bedaquiline treatment in multidrug and extensively drug-

278 At 6 months of bedaquiline treatment, culture conversion was achieved i

279 e susceptibility of 5,036 MDR-TB isolates of bedaquiline treatment-naive patients to bedaquiline and

280 0 and July 2013 and evaluated at 6 months of bedaquiline treatment.

281 ble to all patients with MDR TB, restricting bedaquiline usage to patients with MDR plus additional r

282 Across all parameter sets, the most liberal bedaquiline use strategies consistently increased the ri

283 In almost all cases, more liberal bedaquiline use strategies reduced the expected number o

284 -resistant (MDR) TB patients under different bedaquiline use strategies.

285 pathy (50%), not customarily associated with bedaquiline use, and QTc prolongation (43%).

286 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).

287 p<0.01) were higher among patients receiving bedaquiline versus delamanid.

288 < .01), were higher among patients receiving bedaquiline versus delamanid.

289 e median minimum inhibitory concentration of bedaquiline was 0.25 mg/L (IQR 0.12-0.25) in mmpR5-disru

290 line displayed bactericidal activity whereas bedaquiline was almost inactive.

291 Bedaquiline was associated with a median of 4 (range, 2-

292 Delayed initiation of bedaquiline was independently associated with failure to

293 Bedaquiline was recommended by the World Health Organiza

294 /mL) were active against M chimaera and that bedaquiline was the most potent compound (mean MIC 0.02

295 Here, to understand how MmpS5L5 effluxes bedaquiline, we determined the structure of the MmpS5L5

296 on ART and initiating MDR-TB treatment with bedaquiline were enrolled at a public hospital in KwaZul

297 Although more babies exposed to bedaquiline were of low birth weight, over 80% had gaine

298 favorable outcomes; 88% of babies exposed to bedaquiline were thriving and developing normally compar

299 a matched control group who did not receive bedaquiline, were identified from the electronic tubercu

300 long-acting bedaquiline (alone or with oral bedaquiline with or without rifapentine), and four compa

301 lus short (2-4 wk) oral companion courses of bedaquiline, with or without rifapentine, using the vali